<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2020</study_start_year><data_sharing_plan>IPD Sharing (as of January 2020): No</data_sharing_plan><condition>Apatinib</condition><condition>Outcome, Fatal</condition><condition>Colorectal Cancer</condition><condition>Colorectal Neoplasms</condition><condition>Adjuvant Chemotherapy</condition><disease>Apatinib</disease><disease>Outcome, Fatal</disease><disease>Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><disease>Adjuvant Chemotherapy</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2250127</full_dataset_link><location>China</location><study_start_month>3</study_start_month><keyword>Apatinib</keyword><repository>ECRIN MDR</repository><study_status>Withdrawn</study_status></additional><is_claimable>false</is_claimable><name>Apatinib for Resectable Colorectal Cancer</name><description>Objective: To compare the outcome of patients with colorectal cancer who treated with adjuvant therapy or Apatinib with adjuvant therapy postoperatively.
Language: English.</description><dates><creation>2020-03-15</creation></dates><accession>2250127</accession><cross_references><ClinicalTrials___gov>NCT03228043</ClinicalTrials___gov></cross_references></HashMap>